Terms: = Leukemia AND GATA3, HDR, 2625, ENSG00000107485, MGC5445, MGC5199, MGC2346 AND Clinical Outcome
3 results:
1. High expression of miR-363 predicts poor prognosis and guides treatment selection in acute myeloid leukemia.
Zhang H; Zhang N; Wang R; Shao T; Feng Y; Yao Y; Wu Q; Zhu S; Cao J; Zhang H; Li Z; Liu X; Niu M; Xu K
J Transl Med; 2019 Apr; 17(1):106. PubMed ID: 30935386
[TBL] [Abstract] [Full Text] [Related]
2. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma.
Iqbal J; Wright G; Wang C; Rosenwald A; Gascoyne RD; Weisenburger DD; Greiner TC; Smith L; Guo S; Wilcox RA; Teh BT; Lim ST; Tan SY; Rimsza LM; Jaffe ES; Campo E; Martinez A; Delabie J; Braziel RM; Cook JR; Tubbs RR; Ott G; Geissinger E; Gaulard P; Piccaluga PP; Pileri SA; Au WY; Nakamura S; Seto M; Berger F; de Leval L; Connors JM; Armitage J; Vose J; Chan WC; Staudt LM;
Blood; 2014 May; 123(19):2915-23. PubMed ID: 24632715
[TBL] [Abstract] [Full Text] [Related]
3. FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors.
Neumann M; Coskun E; Fransecky L; Mochmann LH; Bartram I; Sartangi NF; Heesch S; Gökbuget N; Schwartz S; Brandts C; Schlee C; Haas R; Dührsen U; Griesshammer M; Döhner H; Ehninger G; Burmeister T; Blau O; Thiel E; Hoelzer D; Hofmann WK; Baldus CD
PLoS One; 2013; 8(1):e53190. PubMed ID: 23359050
[TBL] [Abstract] [Full Text] [Related]
